1.
Nat Cancer
; 2(8): 794-802, 2021 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35118423
RESUMO
Only a minority of patients derive long-term clinical benefit from anti-PD1/PD-L1 monoclonal antibodies. The presence of tertiary lymphoid structures (TLS) has been associated with improved survival in several tumor types. Here, using a large-scale retrospective analysis of three independent cohorts of cancer patients treated with anti-PD1/PD-L1 antibodies, we showed that the presence of mature TLS was associated with improved objective response rate, progression-free survival, and overall survival independently of PD-L1 expression status and CD8+ T-cell density. These results pave the way for using TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.
Assuntos
Neoplasias Pulmonares , Estruturas Linfoides Terciárias , Anticorpos Monoclonais/uso terapêutico , Antígeno B7-H1/uso terapêutico , Humanos , Inibidores de Checkpoint Imunológico/farmacologia , Neoplasias Pulmonares/tratamento farmacológico , Estudos Retrospectivos
2.